Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions
about
Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in miceAdjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen.Intranasal delivery of recombinant parvovirus-like particles elicits cytotoxic T-cell and neutralizing antibody responses.Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodesMucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of miceHuman papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA.Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responsesPapillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses.The nature of the attenuation of Salmonella typhimurium strains expressing human papillomavirus type 16 virus-like particles determines the systemic and mucosal antibody responses in nasally immunized mice.Trachea, lung, and tracheobronchial lymph nodes are the major sites where antigen-presenting cells are detected after nasal vaccination of mice with human papillomavirus type 16 virus-like particles.Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1Lymphotoxin plays a crucial role in the development and function of nasal-associated lymphoid tissue through regulation of chemokines and peripheral node addressin.Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine.Oral immunogenicity of human papillomavirus-like particles expressed in potato.Neisseria gonorrhoeae NspA induces specific bactericidal and opsonic antibodies in miceImmunogenicity against human papillomavirus type 16 virus-like particles is strongly enhanced by the PhoPc phenotype in Salmonella enterica serovar TyphimuriumA murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection.Microneedle Vaccination Elicits Superior Protection and Antibody Response over Intranasal Vaccination against Swine-Origin Influenza A (H1N1) in MiceSalmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid feverLow-affinity B cells transport viral particles from the lung to the spleen to initiate antibody responsesMonitoring of vaccine-specific gamma interferon induction in genital mucosa of mice by real-time reverse transcription-PCR.A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody responseOptimized Formulation of a Thermostable Spray-Dried Virus-Like Particle Vaccine against Human PapillomavirusThe toxicity of microcystin LR in mice following 7 days of inhalation exposureHuman papillomavirus infection in the oral cavity of HIV patients is not reduced by initiating antiretroviral therapy.Progress and prospects for L2-based human papillomavirus vaccinesNew approaches to prophylactic human papillomavirus vaccines for cervical cancer preventionListeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-mediated CD4+ and CD8+ T-cell responses after oral immunizationInduction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine.Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1.Gas-filled microbubbles: Novel mucosal antigen-delivery system for induction of anti-pathogen's immune responses in the gut.Unique cellular and humoral immunogenicity profiles generated by aerosol, intranasal, or parenteral vaccination in rhesus macaques.Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.DNA diffusion in mucus: effect of size, topology of DNAs, and transfection reagents.Induction of immune responses against human papillomaviruses by hypervariable epitope constructs.
P2860
Q28751866-0F8039FB-C676-4CDA-9CE1-5F50D0050A9AQ33591055-BBB9DD42-7D88-4385-AE43-C90C6FCB113CQ33643167-29A60DB3-4FB4-4EFF-A850-B15F612E93C3Q33822614-E094BB29-6F4E-4E90-923A-E6080C59D2C1Q33823755-1C882296-54ED-4188-8CFD-DC1DD3111AC4Q33840918-71EA360F-EAEA-4047-9224-DF32AC221DD2Q33846577-B24D4768-9971-4B37-873B-BAE95F959BFFQ33847557-F14BD9A2-70D3-438F-8100-0F7826F92BA0Q33877406-F145306B-9F2B-41C7-975C-7F931470488AQ34353473-1BE81495-7673-4D9F-8FF1-F605B70E7824Q34434903-498B2AF0-73F2-4F66-9582-D30CA34AE7D3Q35083503-0607A426-5DB1-4938-9564-2E741DC30465Q35112676-E2D9A187-557B-4F63-B184-833BFDE62C5BQ35182055-53741FB2-F4A9-418E-82DE-795483794332Q35530224-22D89902-5B32-41AD-9751-BDC5A2B061C4Q35550509-4C70CB61-656B-479E-A8BF-0C217941F63AQ35599310-80B10C83-2DA7-475F-BBDA-48186A185F48Q35667123-47872A14-21B5-4EC8-A89E-9B375068B033Q36313476-2EF6A546-2061-4ABB-BFAC-FD5B5DFFD9CDQ36483586-4B35F4DB-110E-4062-A28C-DF679779ED13Q36672549-E99E0138-E745-47E1-B3F7-DAEEEE2595B4Q36673310-9CB1D6F2-AFFB-4C52-B4FF-920517E0B728Q36858686-7DB9B697-C9E4-4F61-8C99-24370C66616AQ36906603-B565B267-8242-4D92-AB3F-2527FA6912BBQ36988090-91190C45-A5E2-49BE-90C4-C8A4E27899BFQ37014047-6647F863-6C80-4413-9021-976B8E01E24AQ37274559-DD777BA0-3E48-445E-9CD0-3E68E66F5254Q37391175-905BFA07-18A0-4D63-A355-07FB441381F2Q37461092-98EFD1BE-BFF9-42DA-A6CC-7DD9FF8ACF05Q37596462-E09C3D1A-0B07-4A27-AE55-2451549DB4E7Q38765335-D1D920FD-5CBE-4629-9B51-EFC3A6403E02Q39045080-EAF9BE3B-91A6-4C10-A08D-3905904687F0Q39742082-F50AD645-CC7B-4066-A9BA-BCC642141D91Q41666565-E9D63180-5A8E-4B8D-956F-733FA49AD99FQ46353574-B4ADA184-0B73-4EC5-BC90-91B2D7E2AC27
P2860
Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions
description
1998 nî lūn-bûn
@nan
1998 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Nasal immunization of mice wit ...... tibodies in mucosal secretions
@ast
Nasal immunization of mice wit ...... tibodies in mucosal secretions
@en
type
label
Nasal immunization of mice wit ...... tibodies in mucosal secretions
@ast
Nasal immunization of mice wit ...... tibodies in mucosal secretions
@en
prefLabel
Nasal immunization of mice wit ...... tibodies in mucosal secretions
@ast
Nasal immunization of mice wit ...... tibodies in mucosal secretions
@en
P2093
P2860
P1433
P1476
Nasal immunization of mice wit ...... tibodies in mucosal secretions
@en
P2093
P2860
P304
P577
1998-10-01T00:00:00Z